Monday, October 17, 2022 from 1:45 PM to 3:15 PM PDT at Continental Ballroom 6
Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-22-193-L01-P
Activity Type: An Application-Based Activity
Building on content in PSAP 2022 Book 1 (Cardiology), this 90-minute program will provide up-to-the-minute information on optimal therapy for HFrEF, on the use of oral anticoagulants in patients with antiphospholipid syndrome, and on the management of antithrombotic therapy in cardiac interventions. A total of 1.5 BCPS credits are available to session attendees who purchase and successfully submit a separate posttest (available Nov. 9, 2022). If you have not already purchased the posttest and wish to add it to your registration, email [email protected] or visit the registration desk on or before Oct. 18, 2022.
 | Speaker: Craig J. Beavers, Pharm.D., FCCP, BCCP, BCPS
View Biography |
 | Speaker: Kelly M. Rudd, Pharm.D., FCCP, BCPS
Clinical Associate Professor of Medicine - Oklahoma State University Center for Health Sciences College of Osteopathic Medicine, Tulsa, Oklahoma
Clinical Pharmacy Specialist - Indian Health Service, Claremore, Oklahoma
View Biography |
 | Speaker: Stephanie Dwyer Kaluzna, Pharm.D.
Clinical Assistant Professor / PGY2 Cardiology Residency Program Director, University of Illinois Chicago College of Pharmacy
Cardiovascular Clinical Pharmacist, University of Illinois Hospital and Health Sciences System
Chicago, Illinois
View Biography |
Learning Objectives
1. Develop a pharmacologic treatment plan for HFrEF and HFpEF that optimizes the use of traditional guideline-directed medical therapy.
2. Distinguish the thrombotic pathophysiology of antiphospholipid syndrome (APS).
3. Evaluate available evidence pertaining to the use of anticoagulants in patients with APS.
4. Develop an appropriate guideline-driven pharmacotherapeutic treatment plan for a patient with APS.
5. Design an antithrombotic treatment plan for a patient undergoing coronary stenting.
6. Analyze recent literature surrounding modified regimens of dual antiplatelet therapy in patients with coronary artery disease and acute coronary syndromes.